Spire Wealth Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Spire Wealth Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-602	Closed	-$2K	–	2967
2021 Q4	$2K	Buy	+602	New	+$2.23K	﹤0.01%	2833
2021 Q2	–	Sell	-602	Closed	-$3K	–	3054
2021 Q1	$3K	Buy	+602	New	+$2.73K	﹤0.01%	2795

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Spire Wealth Management's ZYNE Position: Q1 2022 in Review

Spire Wealth Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 602 shares — an estimated $2K sold.

Spire Wealth Management first reported a position in ZYNE in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

Spire Wealth Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
Spire Wealth Management sold 602 Zynerba Pharmaceuticals, Inc shares in Q1 2022, an estimated $2K.
Spire Wealth Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 2 quarters.
Spire Wealth Management's Zynerba Pharmaceuticals, Inc position peaked at $3K in Q1 2021.
59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.